Percutaneous MR-guided whole-gland prostate cancer cryoablation: safety considerations and oncologic results in 30 consecutive patients.

To assess the safety and oncological efficacy of percutaneous MR-guided whole-gland prostate cancer (PCa) cryoablation (CA).

Between July 2009 and January 2018, 30 patients (mean age 72.9 ± 5. 13 years) with histologically-proven, organ-confined (≤ T 2cN0M0), predominantly low/intermediate-risk PCa (median Gleason score 7; mean PSA 6.05 ± 3.74 ng ml-1 ) underwent MR-guided whole-gland CA. Patients were selected on the basis of prior pelvic radiotherapy (n = 16; 12 for previous PCa), or contra indication/refusal of surgery or radiotherapy. Complications, local progression-free-survival (LPFS) and overall-survival (OS) were retrospectively investigated.

Eighteen [60%] patients reported procedure-related complications: 5/18 [28%] needed surgical/interventional treatments and 13 [72%] conservative or pharmacological treatment. Eleven [73%] complications were noted in the first 15 patients and 7 [47%] in the last 15 patients (p = 0.26). Mean nadir PSA was 0.24 ± 1.5 ng ml-1 (mean follow-up 3.8 years; range: 2 - 2915 days). Seven [23%] patients developed histologically proven local progression (mean time to recurrence 775 days, range: 172 - 2014). Mean clinical follow-up was 3.8 years (range 1 - 2915 days). LPFS was 92.0%, 75.7 and 69.4 % at 1-, 3- and 5 year follow-up, respectively. For patients with prior radiotherapy, LPFS was 100%, 80%, and 80 % at 1-, 3- and 5 year follow-up. OS was 100%, 94.4 and 88.5 % at 1-, 3- and 5 year follow-up respectively, with no patients dying from PCa.

Whole-gland PCa CA offers good oncological efficacy, particularly in post-radiotherapy cases. Although the complication rate is significant, the majority is minor and is managed with conservative or pharmacologic management.

MRI-guided whole-gland prostate cancer cryoablation offers good oncological efficacy, particularly in post-radiotherapy cases with a contained complication rate.

The British journal of radiology. 2019 Mar 08 [Epub ahead of print]

Marini Pierre DE, Cazzato Roberto Luigi, Garnon Julien, Tricard Thibault, Koch Guillaume, Tsoumakidou Georgia, Ramamurthy Nitin, Lang Hervé, Gangi Afshin

1 Department of Interventional Radiology, University Hospital of Strasbourg, 1 Place de l'Hôpital , Strasbourg , France., 2 Department of Urology, University Hospital of Strasbourg, 1 Place de l'Hôpital , Strasbourg , France., 4 Department of Radiology, Norfolk and Norwich University Hospital , Norwich , UK.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe